Overview
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Work here?Claim your company
About Tango Therapeutics
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, MA
Founded
2017
Get referred to Tango Therapeutics
See people who can refer or advise you
Simplify's take
What believers are saying
- October 23, 2026 ESMO data showed 82% ORR and 88% nine-month PFS in PDAC.
- Tango plans a Phase 3 launch in first-half 2027, extending the catalyst runway.
- Robert Azelby joined the board June 22, 2026, adding oncology commercialization experience.
What critics are saying
- October 2026 layoffs cut 14% of staff and gutted the research group.
- Collaboration revenue fell to zero in Q3 2026 after Gilead ended in August 2025.
- If vopimetostat misses Phase 3, Tango becomes a single-asset story with weak bargaining power.
What makes Tango Therapeutics unique
- Tango’s MTAP-deletion focus targets a large, genetically defined cancer subset across solid tumors.
- Vopimetostat pairs synthetic lethality with Revolution Medicines’ RAS(ON) inhibitors in PDAC and NSCLC.
- The company refocused in October 2026 on PRMT5 programs, concentrating capital and talent.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.5B
Above
Industry Average
Funded Over
8 Rounds
Benefits
- Hybrid Work Options
Stock Price
Growth & Insights and Company News
6 month growth
0%1 year growth
-2%2 year growth
-2%Investors reacted sharply to cancer data at the European Society for Medical Oncology (ESMO) meeting, and good results did not always lift shares. Moderna's shares fell by double digits after it and Merck & Co. presented details on their personalised cancer vaccine, intismeran autogene. Investors want more data on other tumour types and on the commercial outlook for a vaccine made through a complex, personalised process. Tango Therapeutics fell about 20% despite an 82% response rate for its pancreatic cancer drug combination. It also announced plans to lay off 14% of its workforce, and analysts cited rising competition. Xencor was a top winner. Its kidney cancer antibody, XmAb819, showed a 46% response rate at the highest dose tested.
Tango Therapeutics (TNGX) expected to post earnings on Tuesday. October 27, 2026 Key points. * Tango Therapeutics is expected to report Q3 2026 results before the market opens Tuesday, November 3. Analysts anticipate a loss of $0.353 per share and revenue of approximately $3.28 million. * The company previously reported a third-quarter loss of $0.37 per share, missing estimates by $0.05. Analysts project full-year and next-year losses of $1.41 and $1.60 per share, respectively. * TNGX shares opened at $22.19 and were down 4.9%. Despite recent insider selling and mixed analyst opinions, the stock has a "Moderate Buy" consensus rating and an average price target of $44.62. * Tracking Tango Therapeutics through earnings season? MarketBeat All Access sends real-time alerts on ratings, earnings, and news - $149 a year, locked in for as long as you stay. Tango Therapeutics (NASDAQ:TNGX - Get Free Report) is projected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Tango Therapeutics to post earnings of ($0.3530) per share and revenue of $3.28 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET. Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts expect Tango Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year. Tango Therapeutics trading down 4.9%. TNGX stock opened at $22.19 on Tuesday. Tango Therapeutics has a fifty-two week low of $7.12 and a fifty-two week high of $34.39. The stock has a fifty day moving average of $23.85 and a 200-day moving average of $21.94. Insider activity at Tango Therapeutics. In other news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This trade represents a 18.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the business's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider directly owned 59,121 shares in the company, valued at approximately $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.50% of the stock is currently owned by company insiders. Analyst upgrades and downgrades. A number of analysts recently weighed in on TNGX shares. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings upgraded Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen lowered Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Mizuho boosted their target price on Tango Therapeutics from $36.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on Tango Therapeutics from $66.00 to $68.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tango Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $44.62. Tango Therapeutics company profile. Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells. Tango's pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tango Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list. While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall. Continue following MarketBeat
Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Key Takeaway: Tango Therapeutics will present updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer at the ESMO Congress 2026. The presentation is scheduled for October 25, 2026, with abstracts available on October 19, 2026. The company will also host a webcast to discuss these findings. Market sentiment analysis. Positive factors. * Tango Therapeutics is presenting updated data at a significant oncology congress. * The study focuses on a promising combination therapy for difficult-to-treat cancers. * The company is committed to precision medicine and innovative cancer treatments. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 7 past catalysts Cash runway Minimal dilution risk Lead asset Phase 1 · PDAC BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation. Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Investors: elizabeth hickin [email protected]. Media: 1AB amanda lazaro [email protected]. Frequently asked questions. What is the focus of Tango Therapeutics' presentation? The presentation focuses on updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib. When will the ESMO Congress 2026 take place? The ESMO Congress 2026 will be held from October 23-27, 2026, in Madrid, Spain. Who will present the updated data? Dr. Alexander I. Spira from NEXT Oncology will present the updated data. How can investors access the webcast? Investors can access the webcast under the 'Events & Presentations' section on Tango's website.
Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET. BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Company Profile Tango Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://tangotx.com Recommended reading.
Tango Therapeutics to participate in the 2026 Cantor Global Healthcare Conference. BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX) ("Tango Therapeutics" or the "Company") today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Tango Therapeutics is Hiring for 16 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Tango Therapeutics
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, MA
Founded
2017
Tango Therapeutics is Hiring for 16 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs